- I. David Weiner, MD – Primary Aldosteronism and the 20-50 Rule, 8/25/23
- Amir Kazory, MD, FASN, FAHA – Diuretic Strategies in Acute Heart Failure; What is New in 2023?, 9/1/23
- Wei Shao, PhD – Prostate Cancer Detection on Micro-ultrasound with Artificial Intelligence, 9/8/23
- Alfonso Santos, MD – Transplantation of Kidneys from HCV-Viremic Donors to HCV-Uninfected Recipients: Contemporary Practice & Outcomes, 9/29/23
- Abhilash Koratala, MD, FASN – POCUS in Cirrhosis-associated AKI: Redefining Diagnostic Frontier, 10/27/23
- Pinaki Sarder, PhD – Segmentation of Kidney Structures, 11/17/23
- Hisham Ibrahim, MD – ABO Incompatible Kidney Transplantation: An Overview of the Past, Present, and Future, 12/1/23
- Parta Hatamizadeh, MD – Mechanical Circulatory Support Devices: The Nephrocardiologic Perspective, 12/15/23
- Wai Lau, MD – Henoch Schonlein Purpura: The Forgotten Love Child, 1/5/24
- Jogiraju Tantravahi, MD – Diabetic Kidney Disease: The past, the present, and hopes for a future, 1/12/24
- Benjamin Shickel, PhD – Digital Health and Opportunities for AI-Enabled Nephrology, 1/19/24
- Muhannad Leghrouz, MD – What does it mean to be a living kidney donor? 2/2/24
- Chintan Shah, MD – Recent Updates in Management of Myeloma-Related Kidney Dysfunction, 2/9/24
- Olesya Ilkun, MD, PhD, FASN – A Walk Through Bone Mineral Disease in CKD, 3/1/24
- Rohan Mehta, MBBS, FASN – Pretransplant Urologic Malignancies: Wait Time to Transplantation and Kidney Transplant Outcomes, 3/29/24
- Rupam Ruchi, MD FASN – Effect of Weight Loss on Kidney Function in Obese Patients with Chronic Kidney Disease, 4/5/24
- Mark Segal, MD, PhD – Focal Segmental Glomerulosclerosis, 4/12/24
- Andrew Slater, DO – Sexual Dysfunction in Chronic Kidney Disease, 5/3/24
- Alejandro Ruiz Toledo, MD – Unclogging the Pipeline: Navigating Constipation in CKD Patients, 5/10/24
- Lina Frauenfeld, MD – Exploring the Relationship Between Depression and CKD, 5/17/24
- Srinath Tripuraneni, MD – Let me sleep, I am tired, 5/24/24
- Issa Haddad, MD – Safety of Pain Medications in Kidney Disease: Choosing an analgesic can be a real pain, 5/31/24
- Ram Sinha, MD – It Takes a Village – Palliative Care and Advanced Care Planning in the CKD/ESRD Patient Population, 6/7/24
- Htun Naing, MBBS – Review of ANCA Associated Vasculitis, 6/14/24
- Ivette Gomez Saavedra – Mesoamerican Nephropathy, 6/21/24
- Daniele Rios Leite, MD – Potassium Binding Resins: A Comprehensive Review, 6/28/24
In this lecture, Daniele Rios, MD, offers a detailed examination of potassium-binding resins and their role in managing hyperkalemia, particularly in patients with chronic kidney disease, heart failure, or those taking renin-angiotensin-aldosterone system inhibitors. Dr. Rios reviews the pharmacologic mechanisms by which these resins bind potassium in the gastrointestinal tract, facilitating its removal and helping maintain safe serum potassium levels.
The lecture covers clinical indications for use, including acute versus chronic management of hyperkalemia, and compares different potassium-binding agents in terms of efficacy, onset of action, and safety profiles. Potential adverse effects, drug interactions, and considerations for special populations are discussed in detail.
Additionally, Dr. Rios highlights evidence-based strategies for integrating potassium-binding resins into comprehensive patient care, including dietary management, monitoring protocols, and individualized treatment planning. Emerging therapies and novel potassium-lowering agents are also explored.
Overall, this lecture equips nephrologists, internists, and healthcare professionals with the knowledge to effectively and safely utilize potassium-binding resins, optimizing management of hyperkalemia while minimizing risks and improving patient outcomes.
In this lecture, Ivette Gomez, MD, provides a comprehensive overview of Mesoamerican nephropathy (MeN), a unique form of chronic kidney disease observed primarily in agricultural communities of Central America. Dr. Gomez discusses the epidemiology, highlighting populations at highest risk, and explores suspected contributing factors, including recurrent dehydration, heat stress, exposure to agrochemicals, and socioeconomic determinants.
The lecture reviews clinical presentation, including reduced kidney function, tubular injury markers, and progression patterns distinct from traditional diabetic or hypertensive kidney disease. Diagnostic strategies, including laboratory evaluation, imaging, and renal biopsy findings, are discussed to help differentiate MeN from other causes of CKD.
Dr. Gomez also highlights current approaches to prevention and management, focusing on occupational health interventions, hydration protocols, early detection, and community-level strategies aimed at mitigating environmental risks. Emerging research and ongoing studies investigating pathophysiology, biomarkers, and potential therapies are also presented.
Overall, this lecture equips nephrologists, public health professionals, and researchers with knowledge about Mesoamerican nephropathy, emphasizing the importance of understanding environmental and occupational risk factors to improve prevention, diagnosis, and care for affected populations.
In this lecture, Htun Naing, MBBS, delivers a comprehensive review of ANCA-associated vasculitis (AAV), a group of rare but potentially severe autoimmune disorders characterized by inflammation of small to medium-sized blood vessels. Dr. Naing discusses the underlying pathophysiology, including the role of antineutrophil cytoplasmic antibodies (ANCAs) in triggering endothelial injury and systemic inflammation.
The lecture covers the spectrum of clinical manifestations, including renal involvement, pulmonary symptoms, and systemic features, and emphasizes the importance of early diagnosis to prevent irreversible organ damage. Diagnostic approaches, including laboratory testing for ANCA subtypes, imaging studies, and biopsy confirmation, are reviewed in detail.
Dr. Naing also presents current treatment strategies, including induction and maintenance immunosuppressive therapy, monitoring for relapse, and management of treatment-related complications. Emerging therapies, risk stratification, and individualized approaches to patient care are highlighted to optimize outcomes.
Overall, this session provides clinicians, nephrologists, and trainees with a thorough understanding of ANCA-associated vasculitis, equipping them to recognize, diagnose, and manage this complex group of disorders effectively.
In this lecture, Ram Sinha, MD, provides a comprehensive overview of palliative care and advanced care planning in the CKD and ESRD patient population. Dr. Sinha highlights the complex physical, emotional, and social challenges faced by these patients and emphasizes the value of a multidisciplinary approach involving nephrologists, nurses, social workers, and palliative care specialists.
The lecture discusses strategies for effective symptom management, including pain, fatigue, pruritus, and psychological distress, as well as approaches to communication that facilitate shared decision-making and align care with patients’ goals and values. Dr. Sinha also addresses the integration of advance directives, end-of-life discussions, and individualized care planning to optimize quality of life while respecting patient autonomy.
Through case studies and practical examples, the session demonstrates how collaborative care and early palliative interventions can improve outcomes for CKD/ESRD patients. Overall, this lecture equips healthcare professionals with the knowledge and tools to provide compassionate, patient-centered care, emphasizing that optimal management of CKD/ESRD requires a team-based “village” approach.
In this lecture, Issa Haddad, MD, provides a comprehensive review of pain management in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), highlighting the challenges of selecting appropriate analgesics that are both effective and safe. Dr. Haddad explores the pharmacokinetics and renal clearance of various pain medications, including NSAIDs, acetaminophen, opioids, and adjuvant agents, and discusses how impaired kidney function impacts drug metabolism and toxicity risk.
The lecture emphasizes evidence-based strategies for minimizing nephrotoxicity, preventing drug accumulation, and avoiding complications such as gastrointestinal bleeding, electrolyte disturbances, and sedation. Dr. Haddad also covers dose adjustments, monitoring requirements, and patient-specific considerations, including comorbidities, concurrent medications, and the stage of kidney disease.
Additionally, the session addresses practical approaches for chronic pain management, non-pharmacologic interventions, and multidisciplinary collaboration to optimize patient comfort while preserving renal function. By integrating clinical guidelines, case studies, and expert recommendations, this lecture equips healthcare providers with the knowledge to choose safe and effective analgesics for patients with kidney disease, balancing pain control with patient safety.
In this lecture, Srinath Tripuraneni, MD, provides a comprehensive overview of sleep disorders in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD). Dr. Tripuraneni discusses the prevalence and types of sleep disturbances in this population, including insomnia, restless legs syndrome, sleep apnea, and circadian rhythm disorders, and explores their impact on physical health, mental well-being, and overall quality of life.
The lecture reviews pathophysiologic mechanisms linking kidney disease to sleep disruption, such as uremia, electrolyte imbalances, anemia, and comorbid conditions. Dr. Tripuraneni also highlights diagnostic approaches, including sleep studies, questionnaires, and clinical assessment tools, to identify and characterize sleep problems accurately.
Management strategies are discussed in detail, including behavioral interventions, pharmacologic therapies, and optimization of dialysis schedules. The lecture emphasizes the importance of a multidisciplinary approach involving nephrologists, sleep specialists, and allied healthcare providers to improve sleep quality and patient outcomes.
Overall, this session equips healthcare professionals with practical knowledge and strategies to address sleep disturbances in CKD and ESRD patients, aiming to reduce fatigue, enhance quality of life, and support overall kidney health.
In this lecture, Lina Frauenfeld, MD, provides a comprehensive overview of the bidirectional relationship between depression and chronic kidney disease (CKD). Dr. Frauenfeld discusses how CKD can contribute to the development of depression through physiological changes, chronic inflammation, medication burden, lifestyle limitations, and psychosocial stressors. Conversely, depression can negatively affect CKD outcomes by influencing adherence to treatment, dietary restrictions, and engagement with healthcare.
The lecture reviews evidence on the prevalence of depression among CKD patients, highlighting high-risk populations and the impact of comorbidities. Dr. Frauenfeld covers diagnostic strategies, including validated screening tools and clinical assessment methods, as well as management approaches that integrate pharmacologic therapies, psychotherapy, lifestyle interventions, and multidisciplinary support.
Additionally, the session emphasizes the importance of early identification and intervention to improve patient outcomes, reduce hospitalizations, and enhance quality of life. Emerging research on the pathophysiologic links between depression and CKD, including inflammatory pathways and neurohormonal mechanisms, is also explored.
Overall, this lecture equips nephrologists, primary care providers, mental health professionals, and allied healthcare teams with the knowledge to recognize, assess, and manage depression in CKD patients, promoting holistic care and better long-term outcomes.
In this lecture, Alejandro Ruiz Toledo, MD, provides a comprehensive overview of constipation in CKD patients, a common yet often underrecognized complication that can significantly impact quality of life. Dr. Ruiz Toledo explores the multifactorial causes of constipation in this population, including dietary restrictions, fluid limitations, medication side effects, reduced physical activity, and comorbid conditions.
The lecture reviews the potential consequences of untreated constipation, such as impaired nutrient absorption, abdominal discomfort, increased risk of gastrointestinal complications, and impact on adherence to CKD management plans. Dr. Ruiz Toledo also discusses evidence-based interventions, including dietary modifications, fiber supplementation, safe use of laxatives, and lifestyle adjustments tailored to CKD patients.
Special considerations for pharmacologic management, including drug selection and dosing adjustments to prevent electrolyte disturbances or worsening renal function, are highlighted. The lecture also emphasizes patient education and monitoring to ensure safe and effective symptom control.
Overall, this session equips nephrologists, primary care providers, and allied healthcare professionals with practical strategies to recognize, prevent, and manage constipation in CKD patients, improving comfort, adherence to treatment, and overall quality of life.
In this lecture, Andrew Slater, DO, provides a comprehensive overview of sexual dysfunction in CKD, a common but often underreported complication affecting both men and women. Dr. Slater discusses the multifactorial etiology of sexual dysfunction in this population, including hormonal imbalances, vascular changes, uremic toxicity, medication side effects, psychological factors, and comorbid conditions.
The lecture reviews the clinical impact of sexual dysfunction, including decreased quality of life, relationship challenges, and psychological distress. Dr. Slater presents diagnostic approaches, including history-taking, questionnaires, and relevant laboratory tests, emphasizing a patient-centered and sensitive approach to care.
Management strategies are explored, including pharmacologic therapies, hormone replacement considerations, lifestyle interventions, counseling, and addressing contributing factors such as depression and medication effects. The lecture also highlights the importance of multidisciplinary collaboration between nephrologists, primary care providers, and mental health specialists to provide comprehensive care.
Overall, this session equips clinicians with the knowledge and practical tools to identify, assess, and manage sexual dysfunction in CKD patients, improving patient well-being, relationships, and overall quality of life.
In this lecture, Mark Segal, MD, PhD, delivers a comprehensive review of focal segmental glomerulosclerosis (FSGS), a primary glomerular disorder characterized by scarring of segments of some glomeruli, often leading to proteinuria and progressive kidney dysfunction. Dr. Segal discusses the pathophysiology of FSGS, including podocyte injury, genetic predisposition, and adaptive mechanisms contributing to glomerular sclerosis.
The lecture covers the spectrum of clinical presentation, from asymptomatic proteinuria to nephrotic syndrome, and highlights diagnostic approaches, including laboratory testing, urinalysis, kidney biopsy, and imaging studies to differentiate primary versus secondary FSGS.
Management strategies are explored in detail, including immunosuppressive therapy, renin-angiotensin system blockade, lipid management, and emerging therapies targeting podocyte injury. Dr. Segal also discusses prognosis, risk factors for progression, and strategies to reduce recurrence, particularly in kidney transplant recipients.
Overall, this session equips nephrologists, trainees, and healthcare professionals with a thorough understanding of FSGS, enabling accurate diagnosis, evidence-based treatment, and improved long-term kidney outcomes.
In this lecture, Rupam Ruchi, MD, provides a comprehensive analysis of the effects of weight loss on kidney function in obese patients with CKD. Dr. Ruchi discusses how obesity contributes to CKD progression through mechanisms such as glomerular hyperfiltration, inflammation, insulin resistance, hypertension, and metabolic dysregulation.
The lecture reviews clinical evidence from lifestyle interventions, dietary modification, pharmacologic therapies, and bariatric surgery demonstrating the impact of weight reduction on proteinuria, glomerular filtration rate, blood pressure, and cardiovascular risk. Dr. Ruchi also highlights practical considerations for tailoring weight loss strategies to patients with CKD, emphasizing safety, adherence, and long-term sustainability.
Additionally, the session addresses challenges and barriers to effective weight management in CKD, including comorbidities, patient motivation, and socioeconomic factors. Emerging research and future directions for integrating obesity management into nephrology care are discussed.
Overall, this lecture equips nephrologists, primary care providers, and allied healthcare professionals with evidence-based strategies to utilize weight loss as a therapeutic tool, improving kidney function, slowing disease progression, and enhancing overall patient health in obese CKD populations.
In this lecture, Rohan Mehta, MBBS, FASN, provides a detailed review of pretransplant urologic malignancies and their relevance to kidney transplantation. Dr. Mehta explores the types of urologic cancers commonly encountered in transplant candidates, including prostate, bladder, and renal cell carcinoma, and examines the risks these malignancies pose for post-transplant outcomes.
The lecture discusses guidelines and evidence regarding recommended wait times between cancer treatment and kidney transplantation, balancing the risk of cancer recurrence with the need for timely transplant. Dr. Mehta also reviews data on post-transplant survival, graft outcomes, and recurrence rates, highlighting factors that influence prognosis.
Clinical considerations, including patient selection, surveillance protocols, and multidisciplinary coordination between nephrology, oncology, and transplant teams, are emphasized. The session also addresses emerging strategies for risk stratification and individualized transplant planning in patients with a history of urologic malignancy.
Overall, this lecture equips transplant physicians, nephrologists, and multidisciplinary care teams with the knowledge to safely navigate kidney transplantation in patients with pretransplant urologic cancers, optimizing timing, outcomes, and patient safety.
In this lecture, Olesya Ilkun, MD, PhD, FASN, delivers a comprehensive review of chronic kidney disease–mineral and bone disorder (CKD-MBD), a complex condition affecting mineral metabolism, bone structure, and vascular health in CKD patients. Dr. Ilkun discusses the underlying pathophysiology, including disturbances in calcium, phosphate, parathyroid hormone, and vitamin D homeostasis, and how these contribute to bone fragility and vascular calcification.
The lecture covers clinical manifestations, including bone pain, fractures, growth impairment, and cardiovascular complications, emphasizing the importance of early recognition and monitoring. Diagnostic approaches, such as laboratory testing, imaging, and bone turnover markers, are reviewed to guide appropriate evaluation and treatment.
Management strategies are discussed in detail, including dietary interventions, phosphate binders, vitamin D analogs, calcimimetics, and other pharmacologic and non-pharmacologic therapies. Dr. Ilkun also highlights emerging research and novel approaches to optimize bone and mineral health while minimizing complications in CKD patients.
Overall, this session equips nephrologists, endocrinologists, and healthcare providers with the knowledge to understand, diagnose, and manage CKD-MBD effectively, improving bone health, reducing fracture risk, and enhancing overall patient outcomes.
In this lecture, Chintan Shah, MD, provides a comprehensive overview of myeloma-related kidney dysfunction, a common and serious complication in patients with multiple myeloma. Dr. Shah discusses the pathophysiology of kidney injury in this population, including light chain cast nephropathy, amyloidosis, and hypercalcemia-induced nephropathy.
The lecture reviews advances in diagnostic strategies, including serum free light chain assays, urine studies, and kidney biopsy, to enable early recognition of renal involvement. Dr. Shah also examines current treatment approaches, such as rapid initiation of anti-myeloma therapy, hydration protocols, supportive care, and the role of plasmapheresis or dialysis when indicated.
Emerging therapies and updates on novel agents that impact renal outcomes are highlighted, alongside practical considerations for balancing myeloma management with kidney protection. Case studies are presented to illustrate individualized treatment strategies and real-world decision-making.
Overall, this session equips hematologists, nephrologists, and multidisciplinary care teams with the knowledge to recognize, manage, and optimize outcomes for patients with myeloma-related kidney dysfunction, emphasizing timely intervention and evidence-based care.
In this lecture, Muhannad Leghrouz, MD, provides a comprehensive overview of living kidney donation, emphasizing what it truly means to become a donor. Dr. Leghrouz discusses the evaluation process for potential donors, including medical assessments, psychosocial evaluation, and ethical considerations to ensure safety and informed decision-making.
The lecture reviews the surgical aspects of kidney donation, including minimally invasive techniques, perioperative care, and post-operative recovery. Dr. Leghrouz also explores short-term and long-term risks, such as changes in kidney function, hypertension, and other health considerations, alongside strategies for monitoring and maintaining donor health.
Beyond the medical perspective, the session highlights the psychological and social impact of donation, addressing motivations, quality of life, and the emotional significance of helping another person. Ethical considerations, including autonomy, informed consent, and donor advocacy, are emphasized throughout.
Overall, this lecture equips healthcare professionals, transplant teams, and prospective donors with a holistic understanding of living kidney donation, supporting safe practices, informed choices, and appreciation for the life-changing impact of donation.
In this lecture, Benjamin Shickel, PhD, provides a comprehensive overview of digital health innovations and AI applications in nephrology. Dr. Shickel discusses how AI, machine learning, and digital tools can transform kidney care by enabling predictive modeling, risk stratification, early detection of complications, and personalized treatment planning for patients with chronic kidney disease (CKD), acute kidney injury (AKI), and kidney transplant recipients.
The lecture reviews current applications of AI in nephrology, including clinical decision support systems, integration with electronic health records, remote patient monitoring, and telehealth platforms. Dr. Shickel also addresses challenges related to data quality, model interpretability, ethical considerations, and regulatory compliance in deploying AI-driven solutions.
Emerging opportunities for research and future directions are highlighted, demonstrating how AI can enhance predictive accuracy, optimize resource allocation, and support precision medicine approaches. Case studies and real-world examples illustrate successful implementation of digital health tools in clinical practice.
Overall, this session equips nephrologists, researchers, and healthcare professionals with the knowledge to leverage AI and digital health technologies to improve patient outcomes, streamline workflows, and advance the field of nephrology.
In this lecture, Jogiraju Tantravahi, MD, delivers a comprehensive review of diabetic kidney disease (DKD), highlighting its evolution from early recognition to modern management and future therapeutic possibilities. Dr. Tantravahi explores the pathophysiology of DKD, including hyperglycemia-induced glomerular damage, oxidative stress, inflammation, and fibrosis, which contribute to progressive kidney injury.
The lecture reviews historical perspectives on DKD diagnosis and treatment, current evidence-based strategies including glycemic control, blood pressure management, renin-angiotensin-aldosterone system blockade, and newer agents such as SGLT2 inhibitors and GLP-1 receptor agonists. Dr. Tantravahi also discusses emerging therapies and precision medicine approaches that target the underlying mechanisms of DKD, aiming to slow disease progression and improve patient outcomes.
Additionally, the session emphasizes early detection, risk stratification, and multidisciplinary management to optimize care for patients with diabetes and kidney involvement. Case studies illustrate practical applications of these strategies in real-world clinical settings.
Overall, this lecture equips nephrologists, endocrinologists, and healthcare professionals with a thorough understanding of DKD, enabling them to combine historical insights with modern advances to provide effective, patient-centered care while anticipating future innovations.
In this lecture, Wai Lau, MD, provides a comprehensive overview of Henoch-Schönlein Purpura (HSP), a systemic vasculitis characterized by IgA deposition in small vessels. Dr. Lau discusses the epidemiology and clinical spectrum of HSP, highlighting differences in pediatric and adult presentations. Key manifestations, including palpable purpura, arthralgias, gastrointestinal symptoms, and renal involvement, are reviewed in detail.
The lecture explores pathophysiologic mechanisms, including immune complex deposition and complement activation, that contribute to vascular inflammation and kidney injury. Diagnostic approaches are discussed, including laboratory evaluation, urinalysis, and biopsy when indicated, to assess the severity and guide management.
Management strategies are outlined, focusing on supportive care, immunosuppressive therapy for severe or progressive cases, and monitoring for long-term renal complications. Case studies illustrate clinical decision-making and highlight challenges in differentiating HSP from other vasculitides or kidney diseases.
Overall, this session equips nephrologists, pediatricians, and healthcare professionals with the knowledge to recognize, diagnose, and manage Henoch-Schönlein Purpura effectively, with special attention to kidney involvement and long-term outcomes.
In this lecture, Parta Hatamizadeh, MD, provides a comprehensive review of mechanical circulatory support (MCS) devices—including ventricular assist devices (VADs) and extracorporeal support systems—from a nephrocardiologic perspective. Dr. Hatamizadeh discusses the complex interplay between heart failure, MCS, and kidney function, highlighting the risk of acute kidney injury (AKI), chronic kidney disease progression, and other renal complications.
The lecture covers the pathophysiology of cardiorenal interactions in MCS patients, including hemodynamic changes, inflammatory responses, hemolysis, and thromboembolic risk. Dr. Hatamizadeh also reviews monitoring strategies, preventive measures, and therapeutic interventions to protect kidney function, including volume management, pharmacologic support, and timing of renal replacement therapy when indicated.
Practical considerations for interdisciplinary care are emphasized, including collaboration between cardiology, nephrology, critical care, and surgical teams to optimize patient outcomes. Emerging research and evolving device technologies are discussed, highlighting their impact on renal outcomes and long-term prognosis.
Overall, this lecture equips clinicians with the knowledge to anticipate, recognize, and manage renal complications in patients with mechanical circulatory support devices, ensuring coordinated, patient-centered care that addresses both cardiac and renal health.
In this lecture, Hisham Ibrahim, MD, provides a detailed overview of ABO-incompatible (ABOi) kidney transplantation, a strategy that expands the donor pool and offers life-saving options for patients with incompatible blood types. Dr. Ibrahim traces the evolution of ABOi transplantation, from early experimental attempts to modern protocols that have significantly improved safety and outcomes.
The lecture discusses immunologic challenges inherent to ABO incompatibility, including antibody-mediated rejection, and reviews desensitization protocols, such as plasmapheresis, immunoadsorption, and pharmacologic therapies (e.g., rituximab and IVIG), which enable successful transplantation despite ABO incompatibility. Dr. Ibrahim also examines patient selection, perioperative management, and long-term outcomes, highlighting evidence for graft survival, patient survival, and complication rates.
Future directions, including novel immunomodulatory strategies and precision medicine approaches, are discussed to further optimize ABOi transplant outcomes. The lecture emphasizes multidisciplinary collaboration among nephrologists, transplant surgeons, immunologists, and nursing teams to ensure comprehensive care.
Overall, this session equips transplant professionals and nephrologists with the knowledge to understand, implement, and optimize ABO-incompatible kidney transplantation, improving access to transplantation and patient outcomes.
In this lecture, Pinaki Sarder, PhD, provides a comprehensive overview of kidney structure segmentation using modern computational and imaging techniques. Dr. Sarder discusses the importance of accurately segmenting renal structures—including glomeruli, tubules, and vasculature—for research, diagnostics, and treatment planning.
The lecture covers digital pathology approaches, image processing workflows, and machine learning methods, including deep learning models, to automate and enhance segmentation accuracy. Dr. Sarder highlights challenges such as variability in tissue morphology, staining differences, and the need for robust, reproducible algorithms.
Applications of segmentation are discussed, including quantification of structural changes in kidney disease, integration with spatial omics data, and support for precision medicine approaches. Case studies and examples illustrate how these techniques can advance nephrology research and improve clinical decision-making.
Overall, this session equips researchers, pathologists, and computational scientists with the knowledge to apply advanced segmentation techniques to kidney imaging and pathology, enhancing understanding of renal structure-function relationships and supporting innovation in kidney disease diagnosis and management.
In this lecture, Abhilash Koratala, MD, FASN, provides a detailed review of POCUS (point-of-care ultrasound) in cirrhosis-associated AKI, emphasizing its role in early detection, differential diagnosis, and bedside decision-making. Dr. Koratala discusses the challenges of diagnosing AKI in patients with cirrhosis due to hemodynamic alterations, volume shifts, and overlapping clinical presentations.
The lecture demonstrates how POCUS can help distinguish between prerenal azotemia, hepatorenal syndrome, and intrinsic renal injury by assessing cardiac function, intravascular volume status, and renal perfusion. Techniques, interpretation tips, and case-based examples are provided to illustrate real-world applications and improve diagnostic accuracy.
Dr. Koratala also highlights the integration of POCUS into clinical workflows, the benefits of rapid bedside assessment, and the potential to guide therapeutic interventions such as fluid management, vasoactive therapy, and early nephrology consultation.
Overall, this session equips nephrologists, hepatologists, and critical care providers with practical knowledge to leverage POCUS in the evaluation of AKI in cirrhotic patients, enhancing diagnostic precision, guiding treatment, and improving patient outcomes.
In this lecture, Alfonso Santos, MD, provides a comprehensive overview of transplanting kidneys from HCV-viremic donors to HCV-uninfected recipients, a strategy that has expanded the donor pool and reduced wait times for kidney transplantation. Dr. Santos discusses the virologic, immunologic, and clinical considerations of this practice, including patient selection, timing of antiviral therapy, and monitoring for HCV transmission and complications.
The lecture reviews contemporary protocols using direct-acting antivirals (DAAs) to prevent or rapidly treat HCV infection in recipients, highlighting efficacy, safety profiles, and the impact on graft and patient survival. Dr. Santos also examines outcomes data, including renal function, infection rates, and long-term follow-up, demonstrating that carefully managed HCV-viremic donor transplants can achieve outcomes comparable to standard donor transplants.
Ethical, logistical, and regulatory considerations are discussed, including informed consent, risk-benefit assessment, and integration into transplant program workflows. Case studies illustrate practical approaches and decision-making in real-world transplant settings.
Overall, this lecture equips nephrologists, transplant surgeons, and care teams with the knowledge to safely implement and optimize kidney transplantation from HCV-viremic donors, improving access to transplantation while maintaining excellent patient and graft outcomes.
In this lecture, Wei Shao, PhD, provides a comprehensive overview of prostate cancer detection using micro-ultrasound combined with AI-based analysis. Dr. Shao discusses the limitations of traditional imaging techniques and the advantages of micro-ultrasound, which offers high-resolution, real-time visualization of prostate tissue.
The lecture highlights how AI algorithms can enhance the interpretation of micro-ultrasound images by identifying suspicious lesions, quantifying risk, and improving diagnostic accuracy. Dr. Shao reviews model development, validation, and integration into clinical workflows, emphasizing how AI can support urologists and radiologists in early detection and treatment planning.
Applications of AI-assisted micro-ultrasound in reducing unnecessary biopsies, guiding targeted interventions, and improving patient outcomes are discussed. Challenges such as algorithm generalizability, regulatory considerations, and clinical adoption are also addressed.
Overall, this session equips clinicians, researchers, and imaging specialists with knowledge of cutting-edge AI-assisted micro-ultrasound techniques, advancing prostate cancer detection, diagnosis, and personalized care.
In this lecture, Amir Kazory, MD, FASN, FAHA, provides a detailed overview of diuretic therapy in acute heart failure (AHF), focusing on recent updates and emerging strategies as of 2023. Dr. Kazory discusses the pathophysiology of fluid overload in heart failure, the mechanisms of action of loop diuretics, thiazides, and combination therapies, and the challenges of diuretic resistance.
The lecture reviews evidence-based approaches to dosing, timing, and route of administration, including continuous versus bolus infusions, sequential nephron blockade, and the role of adjunctive therapies. Dr. Kazory also addresses the impact of diuretic therapy on kidney function, electrolyte balance, and hemodynamics, emphasizing strategies to optimize decongestion while minimizing adverse effects.
Emerging therapies and novel pharmacologic approaches for volume management are highlighted, alongside practical clinical pearls for bedside decision-making. Case studies illustrate real-world application and individualized patient management.
Overall, this session equips cardiologists, nephrologists, and critical care providers with up-to-date knowledge of diuretic strategies in AHF, supporting effective fluid management, improved patient outcomes, and prevention of cardiorenal complications.
In this lecture, David Weiner, MD, provides a comprehensive overview of primary aldosteronism (PA), a common and often underdiagnosed cause of secondary hypertension. Dr. Weiner explains the “20-50 rule,” a practical heuristic for evaluating patients with hypertension for PA: screening is suggested for those with serum potassium ≤2.0 mmol/L or systolic blood pressure ≥150 mmHg on multiple medications, or other high-risk features, emphasizing early detection to improve outcomes.
The lecture reviews the pathophysiology of PA, including autonomous aldosterone secretion, sodium retention, and cardiovascular and renal consequences. Diagnostic strategies, including screening tests (aldosterone-renin ratio), confirmatory testing, and imaging, are discussed to guide patient evaluation and subtype differentiation (unilateral vs. bilateral disease).
Management approaches, including mineralocorticoid receptor antagonists, surgical adrenalectomy, and long-term monitoring, are presented with evidence-based recommendations. Dr. Weiner also highlights case studies demonstrating the application of the 20-50 rule in clinical practice.
Overall, this session equips clinicians with the knowledge to recognize, diagnose, and manage primary aldosteronism effectively, improving blood pressure control, reducing cardiovascular risk, and preserving kidney function.